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ANI Pharmaceuticals, Inc. 
ANIP / NASDAQ 
 
Investment Rating: Sell 
 
PRICE: 73.19  USD  S&P 500: 2,881.40 DJIA: 25,942.37 RUSSELL 2000: 1,572.99 
  
 Using mergers and acquisitions to continue to capture market share 
 Heavily leveraged using debt to finance purchases 
 Remaining competitive for market share of niche and specialty products 
 
 
Valuation 2018 A 2019 E 2020 E 
EPS 1.31 2.98 3.56 
P/E 23.9 12.0 11.6 
CFPS 1.0 .51 .58 
P/CFPS 32.91 70.80 71.24 
 
Market Capitalization Stock Data 
Equity Market Cap (USD): 838,770,000 52-Week Range (USD):    73.19/41.17 
Enterprise Value (USD): 1,010,000,000 12-Month Stock Performance: 
Shares Outstanding (M): 11.88 Dividend Yield:                               0.0 
Estimated Float (M): 9.03 Book Value Per Share (USD):    16.63 
6-mo Avg. Daily Volume (M): 1.136 Beta:                                              1.97 
 
Company Quick View: 
Location:  210 Main Street West, Baudette, MN 56623 United States 
Industry:  Pharmaceutical preparations 325412 / Pharmaceutical Preparation Manufacturing 
NAICS 325412 
Description:  ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company whose 
focus is delivering value to customers and shareholders by developing, marketing, and 
manufacturing high quality branded and generic pharmaceuticals in niche and high barrier to entry 
arenas. 
Key Products & Services:  The main products that ANI Pharmaceuticals Inc. markets and sells are 


























5-year Stock Price 
Performance 
 
      The figure below shows the five year stock price performance graph 
for ANI Pharmeceuticals. Using this figure, we can determine that 
ANIP’s lowest price was $25.62 during July of 2015 and has nearly 
tripled since then closing May 10, 2019 with a stock price of $73.19.  
      In early 2016, the stock price also took a large dip down to the mid-
$30 range before rebounding. From reading their Form 10-K for 2016 I 
have determined that this large dip was due to their acquisition of the 
NDAs (new drug application) for Corticotripin and Corticotrpin Zinc in 
Janauary of 2016, and the market was hesitant that it would be a good 
investment for the company. Their focus was to purchase these NDAs so 








Source: Yahoo Finance 5/11/19 
      ANI Pharmaceutical’s YTD total return as of May 12, 2019 is 
62.57% with an annualized gain of 177.05%. Over the past year the 
stock price has fluctuated greatly, specifically around December 2018 
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3 
where it reached a low of $41.17. Other than that dip that lasted around 




      The previous graph shows a the year-to-date return for ANIP and the 
competitor I have chosen for comparison, Eagle Pharmaceuticals. Over 
the past year and four months, ANIP has gradually provided a much 
better return at 6.49% compared to -1.48% on investment.  
INVESTMENT 
SUMMARY 
      The objective of this analysis was to determine a recommendation 
for shareholders on whether to buy, sell, or hold stock in ANI 
Pharmaceuticals, Inc. Both quantitative and qualitative data were taken 
into consideration regarding ANIP, the industry it operates in, its 
competitors, and economic risk factors. Finally, a discounted cash flow 
model was designed to forecast future free cash flows of the company. 
The model estimated that ANIP’s common stock was overvalued as the 
current stock price is $73.19 and the model calculated the stock to be 
worth $32.91 as of May 12, 2019.  
The current stock price at the market is selling for $41 more than it is 
worth. This should encourage investors to sell now before the market has 





Using my discounted cash flows model I have calculated a stock price 
for ANIP of $31.23 as of December 31, 2018 and $32.91 as of May 12, 
2019. In comparison to what the stock is currently trading at, $73.19, the 
company appears to be heavily overvalued in the market which is a sign 
for investors to sell their stock now to make a profit before the market 
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adjusts. Although I believe ANIP as a company is functioning well in the 
pharmaceutical manufacturing and preparations space I feel that their 
stock is overvalued. The company and the nature of the business takes 
on a large amount of risk and due to multiple mergers, purchase 
agreements, and the high cost of operating in this industry the company 
has been forced to borrow a large amount of long-term debt as well as 
finance a majority of their purchases through shareholder equity. 
Operating in this fashion adds a heavy burden of financial risk to the 
business that is already undertaking high risk for the industry and 













      ANI Pharmaceuticals is an integrated specialty pharmaceutical 
company whose principal offices are in Baudette, MN. Their focus is on 
developing, manufacturing, and marketing generic as well as branded 
prescription pharmaceuticals. Per their 2018 Form 10-K their focus 
within the industry is to “niche and high barrier to entry opportunities 
including controlled substances, anti-cancer, hormones and steroids, and 
complex formulations.” They have manufacturing facilities located in 





      ANI Pharmaceuticals Inc was organized originally as a Canadian 
company in August of 1996 and in December of 1996 was organized in 
Wyoming as Structured Biologicals Inc. In 2001, the company was 
reincorporated in Delaware as Ben-Abraham Technologies Inc. The 
name was then changed to BioSante and this name is still seen attributed 
to the company on occasion. The company acquired ANIP Acquisition 
Company in June of 2013 in a tax-free reorganization and took on the 
name ANI Pharmaceuticals Inc. during this acquisition. Since 2013 
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ANIP has acquired multiple licenses, rights, and interests in different 
drugs as well as other pharmaceutical companies.  
 
      ANIP completed a follow-on public offering in March of 2014 and 
issued Convertible Senior Notes in December of the same year in a 
registered public offering to raise capital. In December of 2018 they 
repurchased about 20% of the previously issued Convertible Senior 
Notes. They also entered into multiple credit agreements with Citizens 
Bank N.A. which allowed them to purchase multiple product rights, drug 
applications, and distribution rights for various products. They 
restructured a majority of these credit agreements as they were set to be 




      The mission of the company is to create long term shareholder value 
by building a sustainable business within the generic and branded 
pharmaceutical market. The company also aims to advance the 
opportunity to re-commercialize Cortrophin gel and Cortrophin-Zinc, 
which they acquired in January of 2016 and is the reason they have a 




      As of December 31, 2018, ANIP has 42 products in their portfolio 
they can offer for sale and distribution. Below is a complete listing of 
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      The markets in which the company operates are based mainly off the 
complexity of the manufacturing process, which usually leads to high 
barriers of entry for other companies. The main markets with these 
distinctions are controlled substances, oncolytics, hormones and steroids, 
and complex formulations. They currently produce five controlled 
substances which are determined by the DEA as a Schedule II substance. 
Their facility in Baudette as well as in Oakville are approved by the 
proper governing authorities to produce these substances on the 
premises. They also have one ANDA (abbreviated new drug application) 
for this specific market. ANIP has three oncolytic, or anti-cancer, drugs 
on the market and they target products which are subject to priority 
review by the FDA. They also focus on hormone and steroid drugs 
primarily to assist in alleviating menopausal symptoms in women, as 
well as treating hormone-sensitive cancers. The complex formulation 
market is targeted since their facilities can already manufacture these 
formulations and this market typically has very high barriers to entry so 
there are less competitors currently. Complex formulations usually relate 
to extended release and combination products. They currently have 
eleven complex formulation products with eight extended- release 




      The main competitors of ANIP are Amneal Pharmaceuticals, 
Amphastar Pharmaceuticals, Creekwood Pharmaceuticals, Eagle 
Pharmaceuticals Inc, Endo Pharmaceuticals, Glenmark Pharmaceuticals, 
Impax Laboratories, Lannett, Mallinckrodt, Mylan, Par Pharmaceutical, 
Purdue Pharma, Roxane Laboratories, Sandoz, Teva Pharmaceuticals, 
and Watson Pharmaceuticals. Many of these companies have a vastly 
different market capitalization than ANIP and specialize in different 
types of products and would not be great candidates for comparison 
purposes. I used Eagle Pharmaceuticals as the comparison company for 
the purpose of this report due to a similar market capitalization. 
 
 
Recent News and Mergers & Acquisitions 
 
      Prior to the completion of the December 31, 2018 financial 
statements and after the close of the period, ANIP terminated all future 
royalty obligations with Teva Pharmaceuticals and paid Teva $16 
million in consideration for the termination of their prior agreement that 
had stated royalties must be paid to Teva for ten ANDAs under a 
purchase agreement.  
 
      In August of 2018, the Canadian subsidiary, ANI Pharmaceuticals 
Canada Inc., acquired all the interest of WellSpring Pharma Services Inc. 
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WellSpring performed contract development services and manufacturing 
of pharmaceutical products within Canada, ANIP bought WellSpring for 
$16.7 million. The purchase included another manufacturing facility, 











      The SIC code for ANIP is 2834 which is the code for pharmaceutical 
preparations industry and the NAICS code for ANIP is 325412 which is 
the industry code for pharmaceutical preparation manufacturing. 
Demand in this industry is driven heavily by government regulation, 






      ANIP has a significant amount of competition within the 
pharmaceutical preparations and manufacturing industry and this is the 
main reason they have tried to find a specific niche of the market to 
target. They specifically work with biotechnology and controlled 
substances to set themselves apart from their competitors. The also aim 
to market drugs that are difficult to develop and produce. One specific 
market ANIP develops products for is the hormone therapy market and 
the reasoning behind this market is that the gaining baby boom 
population is expected to support continued growth in the market as a 
majority of this population is women. Obtaining NDAs and ANDAs 
from government regulations is one of the main ways to stay competitive 
in the prescription drug market. An NDA is a “New Drug Application” 
which is filed when a company would like to market a newly developed 
branded product, new dosage form, or new delivery system. An ANDA 
is filed to receive approval to market a generic equivalent of a drug 
already approved under an NDA. ANIP is constantly researching and 
looking to develop their own NDAs and ANDAs as well as obtain them 









      Pharmaceutical preparation manufacturers require a large supply of 
raw materials to create their products and some of these materials and 
active pharmaceutical ingredients require approval from the Drug 
Enforcement Administration. Specifically, for ANIP, this helps to 
regulate the transport and purchase of highly controlled substances that 
are required to produce several of their products. Without this approval 
on specific amounts that they can purchase they wouldn’t be able to fully 
produce their products. It can take up to 18 months to receive approval 
from the FDA to use certain suppliers for products, thus ANIP usually 
only works with one supplier for the controlled substances that are 
necessary. Due to the high costs of changing suppliers for the non-
controlled raw materials they usually only use one supplier for those 
materials as well, as it is more cost beneficial to purchase in bulk from 
one supplier and maintain a mutual beneficial working relationship with 
them. They have used a few international suppliers in the past and have 
found that some of the shipments from outside the US can be held up in 
transport by the FDA creating delays on receiving the necessary 
supplies. The government regulatory agencies have power over the 





      In recent years the buyers of pharmaceutical products that are 
marketing in this industry have faced heavy consolidation of the 
wholesale distributor networks. The customers of ANIP purchase and 
distribute the products to the end users who are those individuals that are 
ordered a prescription of an ANIP product to help treat an illness. The 
five main customers of ANIP are AmerisourceBergen, Cardinal Health, 
McKesson, Anda, and Morris Dickson who distribute the products 
through three major retail pharmacy chains: CVS, Rite Aid, and 
Walgreens. ANIP also sells to group purchasing organizations and 
national mail order houses such as CVS Caremark, Humana, and 
ExpressScripts. ANIP has less power than their buyers in this situation 
since there are such limited customers to market to due to intense 
consolidation of the pharmaceutical wholesale distributors in recent 
years. As of December 31, 2018, 81% of their net revenues were 
attributed to only three wholesalers meaning that they are open to 
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Threat of Substitution 
 
      The main threat of substitution within the pharmaceutical 
manufacturing and preparations industry would be consumers using 
generic drugs rather than branded drugs or opting for more natural 
homeopathic remedies which do not require conventional prescription 
medications. For the generic substitution, when the life of the patent for 
branded drugs runs out other pharmaceutical companies have the ability 
to formulate generic drugs which can drastically decrease the value of 
the branded drugs. Patents for branded drugs can last up to twenty years 
depending on the type of drug and it uses. ANIP develops both branded 
drugs as well as generic drugs where there is flexibility with existing 
patents. As far as consumers opting for more homeopathic way of 
medicine that can be heavily swayed by demographics and consumer 
attitudes. The ongoing opioid crisis has many consumers blaming 
pharmaceutical companies for a role in the production and promotion of 
drugs that can eventually lead to addiction. This has changed attitudes in 
recent years to try other methods rather than drugs, especially controlled 
substance drugs.  
 
Threat of New Entry 
 
      ANIP has specifically stated that they aim to develop and market 
products that have high barriers to entry thus helping to eliminate 
possible competition and increase their market capitalization. The 
pharmaceutical industry has high barriers to entry such as expensive 
start-up costs, overhead, and personnel needed to operate and develop 
products. Pharmaceutical development, production, and testing are very 
highly regulated by the Food and Drug Administration, Drug 
Enforcement Agency, and the Centers for Medicare and Medicaid 
Services within the United States and other regulatory agencies outside 
the U.S. ANIP specifically deals with the regulatory agencies in Canada 
as well as within the U.S. Patents of new technology related to 
pharmaceutical production as well as applications for new drugs can be 
costly and restrict other companies from being able to recreate the same 
type of drug for up to twenty years before it can be produced in a generic 
form. The economies of scale that are needed to be able to develop and 
produce new drugs is also very great as the technology and knowledge 
required is very costly. Due to the reasons listed above there is a very 
low threat of entry into the industry in which ANIP operates which 
allows them to be less concerned with new competitors arising into the 




















      The peer group of ANIP includes many pharmaceutical companies 
that develop similar products and have similar market caps. I used their 
SIC and NAICS codes to narrow down companies that operate their 
business within the same space. The SIC code for ANIP is 2834 which is 
the code for the pharmaceutical preparations industry and their NAICS 
code is 325412 which is the industry code for pharmaceutical 
preparation manufacturing. For comparison analysis I chose, Amphastar 
Pharmaceuticals Inc., AMAG Pharmaceuticals Inc., and Eagle 
Pharmaceuticals Inc. so that there was a range in their market 
capitalization comparisons but also consistency among their markets and 
industry. 
 
Amphastar Pharmaceuticals, Inc. (AMPH/NASDAQ) 
 
      Amphastar Pharmaceuticals, Inc. (AMPH/NMS) is a specialty 
pharmaceutical company based out of Rancho Cucamonga, California 
that develops, manufactures, markets, and sells both generic and 
proprietary products. They deal mostly with injectables, inhalation and 
intranasal products that aim to treat deep vein thrombosis, opioid 
overdose, asthma and products that screen for adrenocortical 
insufficiency. Amphastar was founded in 1996 and the primary end users 
of its products are hospitals and urgent care locations. The company 
produces 15 injectable products and looks to develop new products that 
have high technical barriers to entry. There is no PE ratio data in the 
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AMAG Pharmaceuticals, Inc. (AMAG/NASDAQ) 
 
      AMAG Pharmaceuticals, Inc. (AMAG/NMS) is a biopharmaceutical 
company based in Waltham, Massachusetts. They focus on developing 
and selling therapeutic products related to maternal and women’s health 
as well as oncology. One of their main values is to produce products for 
patients with currently unmet medical needs. They currently market four 
products that aim to resolves issues with pregnancy complications, 
anemia, menopause issues and women’s sexual function.  
 
Eagle Pharmaceuticals, Inc (EGRX/NASDAQ) 
 
Eagle Pharmaceuticals, Inc. (EGRX/NMS) is a specialty pharmaceutical 
company based out of Woodcliff, New Jersey operating in the specialty 
and generic drug manufacturing space. They focus mainly on oncology 
and critical care developing and manufacturing injectable products.  
Eagle was founded in 2007 and has a similar market capitalization to 
ANIP. Their product line includes four FDA-approved products and they 
have multiple products in development and collaborative agreements. 
Eagle also highly emphasizes safety and efficiency in production so that 
there are limited errors in dosage and use. 
 
From the comparisons on the table below, it is easy to see that both the 
mid-range market capitalization companies, ANIP and EGRX, have been 
providing a much better return to their shareholders based on their return 
on equity as well as being able to adequately use their assets to provide a 
return. The debt to asset ratio is over 0.5 for ANIP which means that the 
company uses more debt than equity to finance their assets while the 
three comparison companies use more equity than debt to finance their 
assets since their ratio is under 0.5. Both AMPH and AMAG has shown 
negative earnings per share for the end of 2018, which explains why they 







Source: MergentOnline as of April 30, 2019 
 
 
Market Cap PE Ratio P/BV EV/EBITDA Debt/Assets ROA ROE
(millions) ttm mrq ttm ttm
ANI Pharmaceuticals Inc ANIP 838.7 mil 54.62 4.27 12.90 0.5419 6.52% 8.33%
Amphastar Pharmaceuticals Inc AMPH 1,010.2 mil N/A 3.16 135.21 0.2905 -1.12% -1.91%
AMAG Pharmaceuticals, Inc. AMAG 362.06 mil N/A 0.51 3.26 0.3648 -2.61% -22.04%











 Source: Company Annual 10-Ks for 2018 
 The above chart displays the amount of expenses allocated to research 
and development for each company. This is a key metric to look at since 
the pharmaceutical manufacturing and sales industry must rely heavily 
on research and development to continue to remain competitive and 
relevant among their competitors. ANIP has the lowest research and 
development expense as well as the lowest percentage of net revenue 
compared to the benchmark companies used in this report. This would 
tell an investor and management that they must start investing more in 
their research and development department in order to remain 
competitive and could also explain why their stock price is currently 










Executives & Key Executives 
 




with ANIP Position 
Arthur S. Przybyl 61 2013 
President and Chief Executive 
Officer 
Stephen P. Carey 47 2016 
Vice President and Chief 
Financial Officer 
James G Marken 55 2016 
Sr. Vice President, Operations 
and Product Development 
Dr. David Sullivan N/A 2014 
Vice President, Quality 
Operations 
Robert Schrepfer 46 2016 
Sr. Vice President, Business 
Development and Specialty 
Sales 
Dr. Mark J. Ginski N/A 2016 
Vice President, Corticotropin 
Product Development 
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Management Incentives and Compensation 
 
      Executives are paid an annual base salary, which is a fixed cash 
compensation plan designed to attract and retain talent. They are also 
offered an annual bonus which is paid as a percentage of their base salary 
in cash and is designed to motivate and reward top executives to achieve 
the company’s goals and foster accountability for continues performance. 
The last portion of executive compensation is the long-term equity awards 
which, in addition to the purposes of the prior compensation components, 
is designed to align compensation with long-term stockholder growth. The 
long-term equity awards are restricted stock and options-based awards 
which vest over four years in equal annual increments, there is no 
guaranteed payout and the awards are at the discretion of the Board upon 
recommendation by the Compensation Committee. 
 
      In 2017, the Compensation Committee also engaged Radford to 
consult on the executive compensation in comparison to 16 peer 
companies. For this engagement the 16 peer companies were as follows: 
Aceto, Acorda Therapeutics, AMAG Pharmaceuticals, Amphastar 
Pharmaceuticals, Depomed, Eagle Pharmaceuticals, Impax Laboratories, 
INSYS Therapeutics, Lannett Company, Momenta Pharmaceuticals, 
Spectrum Pharmaceuticals, Sucampo Pharmaceuticals, Supernus 
Pharmaceuticals, Teligent, Therapeutics MD and Vanda 
Pharmaceuticals. Radford also used their 2017 Global Life Sciences 
Survey, which reviews 33 public biopharmaceutical companies with 
similar net revenues and market capitalizations and used this information 
along with the 16 peer companies to help ANIP determine appropriate 
compensation for 2017 and 2018. As of December 31, 2018, the ratio of 
the CEO’s total compensation to the median employee’s total 
compensation was 80:1, where the median employee’s total 
compensation is $52,389. 
 
ANI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of 
April 1, 2019 is 4. The pillar scores are Audit: 2; Board: 7; Shareholder 
Rights: 1; Compensation: 8. Corporate governance scores are a provided 
by Institutional Shareholder Services (ISS). Scores indicate decile rank 
relative to index or region. A decile score of 1 indicates lower 
governance risk, while a 10 indicates higher governance risk.  
 
      The following table shows the total compensation for a select few on 
































Source: 2018 ANI Pharmaceuticals 10-K Filing 
 
 
Board of Directors 
 
      The Board of Directors (Board) members at ANI Pharmaceuticals 




with ANIP Position 
Robert E. Brown 67 2013 
Independent Chairman of the 
Board of Directors and Chair 




Haughey 54 2018 
Independent Director, Chair 
of the Audit and Finance 
Committee, and Member of 
the Compensation 
Committee 
David B. Nash 62 2018 
Independent Director, 
Member of the Audit and 
Finance Committee, and 
Member of the Nominating 
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Thomas A. Penn 72 2013 
Independent Director, Chair 
of the Compensation 
Committee, and Member of 
the Nominating and 
Corporate Governance 
Committee 
Arthur S. Przybyl 61 2013 
Director, President and Chief 
Executive Officer of ANI 
Pharmaceuticals 
Patrick D. Walsh 57 2018 
Independent Director, 
Member of the Audit and 
Finance Committee, and 




Source: ANI Pharmaceutical’s Website 
 
      The current Board Committees are an Audit and Finance Committee, 
Compensation Committee, and Nominating and Corporate Governance 
Committee. The Audit and Finance Committee assists with oversight of 
the quality and integrity of the financial statements, quarterly reviews 
and annual independent audit. The Compensation Committee is to 
review and set the compensation of the CEO and other executive 
officers, administer the equity compensation plans, review and approve 
strategies for retaining and developing employees, and prepare and 
reports relating to executive compensation required by law. The 
Nominating and Corporate Governance Committee is tasked with 
identifying individuals qualified to become Board members, 
recommends director nominees at the annual meeting, and develops and 
recommends a set of corporate governance standards for the Board to 
adhere to. 
 
      There is no fixed retirement age or term limits to serving as a 
director on the Board. Loans and extensions of credit from ANIP to any 
directors or executive officers are prohibited. The Board also plans for 
succession for the CEO as well as other senior management positions 
that consider death, departure, or disability of any key persons on an 
untimely basis to help facilitate both interim and long-term leadership 
positions. Directors are encouraged but not required to attend continuing 
education programs tailored to directors of publicly-held companies. The 
Board is currently comprised of all male directors, and five out of the six 

















Competitor - Eagle 
Pharmaceuticals, 
Inc. 
2018 6.06% 19.26% 
2017 0.98% 52.14% 
2016 2.67% 56.42% 
2015 9.06% 9.16% 
2014 13.73% -173.86% 
Source: Mergent Online 
 
      The continued positive ROIC of ANIP shows that the company uses 
their invested capital to create profits year after year even when involved 
with mergers and acquisitions of other companies. In comparison, Eagle 
shows that they are much more able to create returns on their invested 
capital as they boast higher percentages than ANIP. While still much 
higher than ANIP, Eagle appears to be fluctuating in its ability to use its 
invested capital to create profit and value for shareholders. As of the end 










      The total number of shares outstanding for ANIP is 11,862,193 as of 
December 31, 2018. Institutional shareholders own 61.76% of the total 
shares of stock while the remaining shares are held by individual 
investors most of which have been insiders at some point and received 
the shares or the option to purchase them from the company as 
compensation. The table below shows the top ten institutional investors 
out of the total 199 shareholders as of December 31, 2018 as well as the 




























Source: Yahoo Finance and NASDAQ.com 
 
      The next table lists the eight largest insider shareholders and their 
percentage ownership relative to the total number of shares outstanding 
for December 31, 2018. The company filed its SEC Form 4 filings as of 














Source: Yahoo Finance and Mergent Online 
 
      The last table illustrates that some of the non-institutional 
shareholders are not currently insider shareholders that earn their shares 
during their time as a director or other position within the company. The 
number of shares owned by these former insiders makes up at least 5% 
of total ownership. Note that the following list is not a complete list, I 













Source: Yahoo Finance 
 
      During 2018, there were multiple insider trading transactions 
reported. Most of these transactions were sales of stock after they had 
been exercised from an option or warrant or stock grants to insiders, 
likely as part of their compensation.  There were 235,179 shares that 
were sold by indirect shareholders compared to 96,815 of shares that 
were sold by insiders during the 2018 calendar year. This indicates that 
the insiders are willing to hold their shares for future value and that the 
outsiders may want their money out now. The company currently does 
not pay dividends and does not plan to any time soon per their 2018 10-
K filing. March of 2014 was the most recent date that the company 
issued common stock in a follow-on public offering. 
      ANIP also has six shareholders that hold their Class C Common 
stock which is not traded on an exchange. This stock allows voting 









      All companies operating in the pharmaceutical preparations and 
manufacturing industry face an immense amount of risk due to the 
nature of the work and the liability that they assume when producing 
products for use on humans. 
 
Consolidation of Customer Groups 
 
      The consolidation of customer groups could lead to increased 
purchasing leverage by these companies or the risk that the consolidated 
company would choose another manufacture. Since the majority of 
ANIP’s sales is linked to only three customers that make up 77% of 
their net revenues for 2018, the threat of consolidation could easily 
disrupt their business and profits. Another effect of consolidation of 
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customer groups is that they could drive down prices for certain drugs 
which could also drastically affect the financial position of ANIP if the 
price decreases were to target one of their markets or drugs. 
 
Products Without FDA Approval 
 
      ANIP produces and markets two products that as of 2018 made up 
12% of their total revenue. There is no certainty that the FDA would not 
require them to apply for approval before continuing to market these 
products. The two products are Esterified Estrogen with 
Methyltestosterone (“EEMT”) and Opium Tincture. These drugs aren’t 
required to be approved before sold but the FDA takes a stance on them 
based on the drugs risks and on a case-by-case basis. ANIP feels 
confident that as long as they comply with manufacturing standards that 
the FDA will not take action. There is no guarantee the FDA won’t take 
action, so it does pose a large risk. The dollar amount of 12% of total 




Governmental Regulation Risk 
 
      Some of the more recent governmental regulations enacted in the 
Affordable Care Act “ACA” required states to expand their Medicaid 
and Medicare programs to additional individuals. Another requirement 
of ACA was that pharmaceutical companies were required to participate 
in rebate programs with Medicaid and other discount programs for 
Medicare. Calculating these rebates and discounts can be complex and 
is on a state by state basis as these programs are operated at the state 
level. ANIP is exposed to risk in its calculations of these rebates and 
discounts as well as to any future government regulations that determine 




      Technology risk covers a broad spectrum of factors for 
pharmaceutical manufacturers including product and process 
innovation, research and development, and knowledge creation. If ANIP 
is not able to continually advance their research and development of 
new drugs there will be other pharmaceuticals companies that will use 
their technological advantage to corner more of their market share. It is 
crucial to stay up to date and continue to be innovation with their 
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Product Liability Risk 
 
      Due to intense pressure from consumers and government alike to 
reduce the costs of prescription drugs this often means that 
pharmaceutical companies need to speed up their research and 
development phases which means the formulations will likely spend 
less time in testing. This could lead to a larger risk with patient safety if 
the products aren’t properly and completely testing due to cost 
restrictions. ANIP bears product liability risk with all their products that 
they market and sell, and it can be very difficult to determine how much 
risk they are exposed to in this area. ANIP does utilize third-party 
insurance policies to help reduce their risk associated with product 
liability. Additional product liability increases the cost of insurance 




       The risk associated with the demographic of consumers relates 
mostly to the age of the population. It was mentioned earlier that ANIP 
expanded into the hormone therapy market due to the fact that the aging 
population of women would continue to support sales and therefor 
research and development in this area, but as the baby boomers age 
there is not as many people to replace them. The company would have 
to continually reassess this risk and determine if this market is still 
profitable and drives shareholder value. Another factor that falls under 
demographic risk would be income distribution, if individuals are not 
able to afford their necessary medications they may either stop 
purchasing them altogether or encourage the government to introduce 
additional legislation that would make pharmaceuticals more affordable 
as was seen in the ACA. 
 
Production, Manufacturing, and Packaging Risk 
 
      ANIP markets several products that they have acquired that they 
cannot manufacture in their facilities. If they cannot find reliable 
contract manufacturer then they would lose the sales of those products. 
There are also several of their products which are manufactured and/ or 
packaged by third parties which leads to the risk of incorrect product 














      I chose Eagle Pharmaceuticals as the competitor for analysis 
purposes and to compare their financial ratios. Eagle has a similar 
market capitalization to ANIP as well as operates within the same 
industry and faces similar industry risks.  
      In analyzing ANIP’s productivity performance, most of the ratios 
have managed to stay consistent with the prior year with either slight 
upticks or downticks gradually overtime. Historically, ANIP’s growth 
in sales increased from 2015 to 2016 and has been declining since 2016 
through 2018. The most recent growth percentage was 14% and when 
compared to Eagle’s growth rate of -9.9% it would indicate that ANIP is 
able to better manage their growth. I would attribute the high spike in 
sales in 2016 to the acquisition of the NDAs for Corticotropin and 
Corticotropin-Zinc as well as the launch of eleven other products that 
were not previously available. 
      ANIP has slightly lower liquidity ratios with their quick ratio being 
0.92 in 2018 while Eagle’s current ratio was 4.13. This means that 
ANIP would not be able to pay all their current liabilities as of the year 
end. ANIP also has longer operating and cash cycles by 63 days and 64 
days, respectively. 
      The Financial risk (leverage) ratios have also remained somewhat 
constant especially in the last four years with a slight downturn from 
2017 to 2018. ANIP’s total debt-to-assets ratio is 0.50, meaning that 
half of their asset base is financed with debt. Eagle’s total debt-to-asset 
ratio is only 0.27. The total debt-to-equity ratio for ANIP is 1.00 while 
Eagle’s is 0.36. This shows that the amount of debt for ANIP matches 
the amount of equity which can be a riskier position to be in than Eagle. 
Most of the financial risk ratios for ANIP show that the company is 
taking on a large amount of financial risk with their borrowing of debt, 
hoping to capitalize on this debt with future returns. 
      Profitability and valuation ratios for ANIP have been fluctuating 
over the previous five years with a gross profit margin ranging from 
55.3% to 83.4%. Most recently the gross profit margin for ANIP was 
63.8% while the same metric for Eagle was 72.7% showing that Eagle 
is able to achieve 8.4% more profitability than ANIP. The ROIC metric 
was discussed previously in the Management Performance section. 
Neither of the companies pay dividends as seems customary with this 
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type of industry. The net margin for ANIP was 7.7% in 2018 and was 
17.4% for Eagle in 2018. ANIP is underperforming the benchmark in 
the profitability performance analysis. 
      Overall the financial ratios, ANIP appears to be underperforming in 
most categories compared to the benchmark of Eagle Pharmaceuticals. 
ANIP looks to be heavily leveraged and that could be too much risk for 










      ANI Pharmaceuticals was able to increase their net income in 2018 
drastically over 2017, they also increased their operating profit which 
looks to be a better indicator of where the company is heading for the 
future. In 2017, the net income was negative which is an anomaly for 
the company over the last five years. This was due to the large amount 
of taxes that was paid that year. The change in tax rates due to the Tax 
Cuts and Jobs Act enacted on December 22, 2017 forced the company 
to revalue their deferred tax assets and liabilities and thus they incurred 
nearly four times as much tax than in the years following or preceding 
2017. 
       I used my discounted free cash flow model to value and calculate 
future financial performance projections for ANIP over the next five 
years. These statements can be found at the end of this analysis paper 
along with applicable financial ratios and those that I calculated for the 
competitor used as a benchmark throughout the analysis, Eagle 
Pharmaceuticals, Inc.  
      I estimated that ANIP’s sales will continue to grow at 14% as was 
the most recent growth rate as well as the trend over the prior five years 
of data. This seems like a likely growth rate to me since the company is 
continuing to acquire new NDAs and ANDAs as well as other 
companies that have the rights to certain sales. Compared to the growth 
rate of Eagle, which was a -9.9% for the previous five years, ANIP is 
doing a much better job of increasing their growth in sales.  
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    The percentage of cost of goods sold (COGS) has steadily increased 
over time as the amount and price of inputs continues to increase in the 
industry. The COGS as a percentage of sales was 20.5% at the end of 
2014 and has increased to 36.2% of sales as of the end of 2018. The 
selling, general, and administrative expenses have actually seen a steady 
decrease from 2014 from 36.5% of sales to 2017 of 23.0% of sales and 
then rose again to 29.8% of sales in 2018. This indicates to me that the 
company is trying to manage their overhead expenses so that they can 





VALUATION        A discounted free cash flow model was used in the valuation of the 
common stock of ANIP. The future financial statements were estimated, 
and the forecasted free cash flows were discounted at the company’s 
weighted average cost of capital (WACC). I calculated a relative 
valuation of ANIP’s competitor, Eagle Pharmaceuticals to assist in 
determining the value of ANIP. I calculated that the price per share was 
to be $31.23 at December 31, 2018 and $32.91 at May 12, 2019, when 
this report was completed.  
       In the model, I calculated the cost of equity using the Capital Asset 
Pricing Model (CAPM). This model required that I make various 
assumptions to determine the weighted average cost of capital. The 
assumptions I used were a market risk premium of 6%, a beta of 1.97, 
and a risk-free rate of 2.5%, pretax cost of short-term debt of 5.5%, 
pretax cost of long-term debt of 6.56%, and a tax rate of 21%. My 
model calculates a WACC of 12.02%.  
       Within my model it calculated the free cash flows using estimates 
to predict the future cash flows and therefore the share price. These 
estimates were typically taken from the averages of the prior five years 
of financial information. There were certain cases where it was 
necessary to use the most recent information instead of the average, 
such as the where taxes were concerned since there was recent 
regulation that changed the companies tax rate from forward from 
January 1, 2018. 
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      Although ANIP had better sales growth than the benchmark they 
were much more heavily leveraged and their ROIC was remarkably 
lower. This combined with the estimated price per share that I 
calculated shows that ANIP is currently priced at a much higher number 
than its actual and future value. I would encourage investors to sell this 
stock before the price realigns with the actual performance of the 
company and drops. I believe there is a good chance that this company 
could be profitable in the future and show a great return on investment 
for shareholders but since it is so overvalued at this time it would not be 
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ANI Pharmaceuticals, Inc.         
In thousands of USD         
Income Statement 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 
Sales 128,622 176,842 201,576 229,797 261,968 298,644 340,454 388,117 
Costs of goods sold (COGS) 48,780 79,032 73,024 83,247 94,902 93,159 106,201 121,070 
Sales, general and administrative expense (SGA) 30,809 40,595 60,001 66,480 75,787 86,397 98,492 112,281 
Depreciation 22,343 27,928 33,742 23,475 26,761 30,508 34,779 39,648 
Operating profit 26,690 29,287 34,809 56,595 64,518 88,580 100,981 115,118 
Interest expense 11,327 12,035 14,758 10,779 9,812 10,701 11,032 11,356 
Interest income - - - - - - - - 
Nonoperating income (Expense) - - - - - - - - 
Earnings before taxes (EBT) 15,363 17,252 20,051 45,816 54,706 77,879 89,949 103,762 
Tax expense 4,744 17,425 4,557 10,413 12,433 17,700 20,443 23,582 
Net income before extraordinary items 10,619 (173) 15,494 35,403 42,273 60,180 69,506 80,180 
After-tax extraordinary income (Expense) - - - - - - - - 
Net income (NI)  10,619 (173) 15,494 35,403 42,273 60,180 69,506 80,180 
         
Dividends-- preferred - - - - - - - - 
Dividends-- common - - - - - - - - 
Additions to RE 10,619 (173) 15,494 35,403 42,273 60,180 69,506 80,180 
Balance Sheet 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 
Assets         
Cash 27,365 31,144 43,008 49,029 55,893 63,718 72,639 82,808 
Inventory 26,183 37,727 40,503 42,630 48,598 55,402 63,158 72,000 
Accounts receivable 45,895 58,788 64,842 73,872 84,214 96,004 109,444 124,767 
Other short-term operating assets 3,564 3,946 4,524 4,973 5,670 6,463 7,368 8,400 
Short-term investments - - - - - - - - 
Total current assets 103,007 131,605 152,877 170,504 194,375 221,587 252,610 287,975 
Net plant, property, & equipment (PPE) 10,998 20,403 38,090 26,500 30,210 34,439 39,261 44,757 
Other long-term operating assets 184,315 240,045 214,240 244,234 278,426 317,406 361,843 412,501 
Long-term investments 5,002 5,006 5,021 4,233 4,826 5,501 6,272 7,150 
Total assets 303,322 397,059 410,228 445,471 507,837 578,934 659,985 752,382 
         
Liabilities and Equity         
Accounts payable (AP) 3,389 3,630 8,884 7,603 8,668 9,881 11,265 12,842 
Accruals 23,428 23,971 27,683 32,654 37,225 42,437 48,378 55,151 
Other operating current liabilities 5,756 8,274 13,263 10,012 11,414 13,012 14,833 16,910 
All short-term debt - 3,353 115,719 64,486 65,795 57,426 47,350 35,331 
Total current liabilities 32,573 39,228 165,549 114,755 123,102 122,756 121,826 120,234 
Long-term debt 120,643 198,154 67,296 95,504 107,955 120,023 133,415 148,271 
Deferred taxes (26,227) (22,667) (27,964) (5,155) (5,877) (6,700) (7,638) (8,707) 
Preferred stock - - - - - - - - 
Other long-term liabilities - - 496 113 129 147 168 191 
Total liabilities 126,989 214,715 205,377 205,217 225,309 236,227 247,771 259,989 
Par plus PIC Less treasury (and other adjustments) 121,592 127,776 134,789 134,789 134,789 134,789 134,789 134,789 
Retained earnings (RE) 54,741 54,568 70,062 105,465 147,738 207,918 277,424 357,604 
Total common equity 176,333 182,344 204,851 240,254 282,527 342,707 412,213 492,393 
Total liabilities and equity 303,322 397,059 410,228 445,471 507,837 578,934 659,985 752,382 
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ANI Pharmaceuticals, Inc.         
In thousands of USD         
Statement of Cash Flows 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 
Operating Activities         
Net income 10,619 (173) 15,494 35,403 42,273 60,180 69,506 80,180 
Depreciation 22,343 27,928 33,742 23,475 26,761 30,508 34,779 39,648 
Change in deferred tax (8,911) 3,560 (5,297) 22,809 (722) (823) (938) (1,069) 
         
Change in inventory (12,796) (11,544) (2,776) (2,127) (5,968) (6,804) (7,756) (8,842) 
Change in accounts receivable (23,963) (12,893) (6,054) (9,030) (10,342) (11,790) (13,441) (15,322) 
Change in other short-term operating assets (984) (382) (578) (449) (696) (794) (905) (1,032) 
Change in accounts payable 1,323 241 5,254 (1,281) 1,064 1,213 1,383 1,577 
Change in accruals 16,386 543 3,712 4,971 4,572 5,212 5,941 6,773 
Change in other current liabilities 3,108 2,518 4,989 (3,251) 1,402 1,598 1,822 2,077 
Net cash from operating activities 7,125 9,798 48,486 70,520 58,344 78,500 90,392 103,990 
         
Investing Activities         
Investment in PPE (26,210) (37,333) (51,429) (11,885) (30,471) (34,737) (39,600) (45,145) 
Investment in other long-term oper. ass. (116,080) (55,730) 25,805 (29,994) (34,193) (38,980) (44,437) (50,658) 
Net cash from investing activities (142,290) (93,063) (25,624) (41,878) (64,664) (73,717) (84,037) (95,803) 
Financing Activities 
Change in short-term investments - - - - - - - - 
Change in long-term investments (5,002) (4) (15) 788 (593) (676) (770) (878) 
Change in short-term debt - 3,353 112,366 (51,233) 1,309 (8,369) (10,076) (12,019) 
Change in long-term debt 7,216 77,511 (130,858) 28,208 12,452 12,068 13,392 14,856 
Preferred dividends - - - - - - - - 
Change in preferred stock - - - - - - - - 
Change in other long-term liabilities - - 496 (383) 16 18 21 23 
Change in common stock (Par + PIC) 5,632 6,184 7,013 - - - - - 
Common dividends - - - - - - - - 
         Net cash from financing activities 7,846 87,044 (10,998) (22,620) 13,184 3,042 2,566 1,982 
         
Net cash flow (127,319) 3,779 11,864 6,021 6,864 7,825 8,921 10,169 
Starting cash 154,684 27,365 31,144 43,008 49,029 55,893 63,718 72,639 
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ANI Pharmaceuticals, Inc.        
        
Ratios     2018 2017 2016 2015 2014 
Productivity Ratios        
     Growth in sales   14.0% 37.5% 68.5% 36.4% N/A 
     Receivables turnover   3.11 3.01 2.80 3.48 3.24 
     Inventory turnover   4.98 4.69 4.91 5.70 7.44 
     Operating working capital turnover   1.96 1.85 1.83 0.42 0.31 
     Net fixed asset turnover   0.80 0.68 0.66 1.01 1.07 
     Total asset turnover   0.49 0.45 0.42 0.28 0.23 
     Invested capital turnover   0.57 0.50 0.48 0.30 0.24 
Liquidity Ratios        
     Current ratio   0.92 3.35 3.16 16.38 14.80 
     Quick ratio   0.68 2.39 2.36 15.24 14.23 
     Cash ratio   0.26 0.79 0.84 13.16 12.77 
     Short-term investments over invested capital 0.00 0.00 0.00 0.00 0.00 
     Operating Cycle 190.75 199.21 204.54 168.91 161.83 
     Cash Cycle   174.66 191.71 194.92 159.03 144.52 
Financial Risk (Leverage) Ratios        
     Total debt-to-equity ratio   1.00 1.18 0.72 0.67 0.78 
     Total debt-to-equity ratio (excluding deferred taxes)  1.14 1.30 0.87 0.78 0.89 
     Total financial debt-to-equity ratio   0.89 1.11 0.68 0.71 0.79 
     Interest coverage ratio (accounting-based)  2.36 2.43 2.36 2.97 25.62 
     Interest coverage ratio (cash-based)   4.65 4.75 4.33 3.60 30.55 
     Total debt-to-assets ratio   0.50 0.54 0.42 0.40 0.44 
     Total financial debt over total assets   0.45 0.51 0.40 0.42 0.45 
     Long-term financial debt over invested capital  0.19 0.56 0.45 0.44 0.47 
Profitability/Valuation Ratios        
     Gross profit margin   63.8% 55.3% 62.1% 83.4% 79.5% 
     EBITDA margin   34.0% 32.4% 38.1% 51.9% 43.0% 
     Operating profit margin   17.3% 16.6% 20.8% 42.9% 36.0% 
     NOPAT margin   10.7% 1.5% 5.3% 27.9% 25.9% 
     Earnings before taxes margin   9.9% 9.8% 11.9% 28.5% 34.6% 
     Net margin   7.7% -0.1% 8.3% 20.1% 51.4% 
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     Return on Assets   8.49% 7.38% 8.80% 12.22% 8.12% 
     Net investment rate   -3.71% 3484.92% 139.62% 99.39% 1623.69% 
     Dividend payout ratio   0.00% 0.00% 0.00% 0.00% 0.00% 
     ROIC   6.06% 0.98% 2.67% 9.06% N/A 
 
Eagle Pharmaceuticals, Inc. – Competitor Analysis      
      
Ratios 2018 2017 2016 2015 2014 
      
Productivity Ratios      
     Growth in sales           (0.10)             0.25              1.86            10.83   N/A  
     Receivables turnover             3.21              4.40              4.49              2.52              0.47  
     Inventory turnover           25.69            46.25            69.18              4.40              4.51  
     Operating working capital turnover             2.07              2.47              2.69              0.37              0.03  
     Net fixed asset turnover             2.76              2.92              2.44            28.21            14.47  
     Total asset turnover             0.89              0.88              1.02              0.53              0.11  
     Invested capital turnover             0.60              0.66              0.71              0.26              0.02  
      
Liquidity Ratios 
     Current ratio             4.13              3.99              2.66              3.57              2.24  
     Quick ratio             3.92              3.88              2.60              3.13              2.18  
     Cash ratio             1.99              2.42              1.29              2.31              1.57  
     Short-term investments over invested capital                -                   -                   -                   -                   -    
     Operating Cycle         127.97            90.88            86.55          227.67          860.23  
     Cash Cycle         111.00            72.41            58.21          206.41          632.04  
      
Financial Risk (Leverage) Ratios      
     Total debt-to-equity ratio             0.36              0.42              0.23              0.38              0.79  
     Total debt-to-equity ratio (excluding deferred taxes)             0.44              0.48              0.41              0.38              0.79  
     Total financial debt-to-equity ratio             0.25              0.26              0.15                 -                   -    
     Interest coverage ratio (accounting-based)           17.90            68.94        6,568.63          232.73      (6,565.00) 
     Interest coverage ratio (cash-based)           18.33            69.76        6,648.75          242.91      (6,552.00) 
     Total debt-to-assets ratio             0.27              0.29              0.18              0.27              0.44  
     Total financial debt over total assets             0.18              0.18              0.12                 -                   -    
     Long-term financial debt over invested capital             0.18              0.19              0.15                 -                   -    
      
Profitability/Valuation Ratios      
     Gross profit margin 72.69% 77.42% 71.65% 76.54% 20.07% 
     EBITDA margin 23.50% 33.48% 28.07% 4.03% -117.00% 
     Operating profit margin 22.96% 33.08% 27.73% 3.87% -117.23% 
     NOPAT margin 20.52% 32.09% 26.90% 3.86% -98.32% 
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     Earnings before taxes margin 21.75% 32.64% 27.77% 3.89% -117.23% 
     Net margin 17.40% 26.19% 43.49% 3.88% -98.32% 
     Return on Assets 20.33% 29.04% 28.16% 2.05% -13.11% 
     Net investment rate -53.18% 101.99% 103.12% 2441.71% -506.87% 
     Dividend payout ratio 0.00% 0.00% 0.00% 0.00% 0.00% 
     ROIC 19.26% 52.14% 56.42% 9.16% N/A 
 
